A Phase 4 interventional study of Bupivacaine in Pain, Postoperative, sponsored by Mayo Clinic. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Mayo Clinic · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 142nd largest by planned enrollment, is one of 25 that started in 2015, is one of 133 in phase 4, reaches primary completion later than 32 of the 59 other live ones, and was the 61st registered.
5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 25 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 88 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
18 studies in Pain, Postoperative by Mayo Clinic: 2 open now, 4 under way, none of them phase 3. Of 14 finished, 9 (64%) have results posted.
Among the 18 studies in Pain, Postoperative by Mayo Clinic, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2015, is one of 10 in phase 4, and was the 4th registered.
Mayo Clinic’s Pain, Postoperative studies by the year they started, since 2006.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
Among Mayo Clinic’s 18 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
After surgery to remove the eye, either by enucleation or evisceration, patients have variable levels of pain for several postoperative days. Some patients have almost no discomfort while others require significant amounts of oral narcotics and report pain of 10 out of 10 on a numerical rating scale. The current operative standard is to infiltrate the eye socket with 0.5% bupivacaine during surgery leading to several hours of postoperative analgesia. In 2011, Pacira Pharmaceuticals released a bupivacaine liposomal injectable suspension (Exparel, 1.3%) which offers sustained release of bupivacaine giving postoperative pain control for up to 72 hours. This medication has been used in numerous surgeries including inguinal hernia repair, hemorrhoidectomy, bunionectomy, breast reconstruction, and orthopedic surgery, and the literature reports improved pain control, decreased use of oral opioids, and increased patient satisfaction. There are no reports of the use of Exparel in the ophthalmic literature. The investigators propose a randomized, controlled trial to compare the postoperative pain control offered by sustained release bupivacaine to that offered by standard plain bupivacaine after enucleation or evisceration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Intraoperative injection of local anesthetic agent, standard of care
Drug: Bupivacaine
Intraoperative injection of local anesthetic agent, long acting agent
Drug: Bupivacaine
Intraoperative orbital injection of local pain medication
Also known as: Exparel
Postoperative orbital pain
Pain on a scale of 0-10, assessed on day 3 post enucleation or evisceration
Time frame: Days 3 postoperatively
Postoperative nausea and vomiting
Nausea and vomiting on a scale of 0-3, assessed on day 3 post enucleation or evisceration
Time frame: Days 3 postoperatively
Quantity of oral narcotics used for postoperative pain control
Number of oral narcotic pills taken during postoperative days 0-3
Time frame: Days 3 postoperatively
Patient satisfaction
Overall satisfaction with postoperative recovery, assessed on a scale of 1-5
Time frame: Day 3 postoperatively
Postoperative complications
Assessment of any postsurgical complications completed at postoperative visit
Time frame: 6-8 weeks postoperatively
Plan to share: Yes — University of Michigan will share patient study data with Mayo site. A Data Use Agreement has been approved for this purpose.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: From July 2024 through end of reporting period.
The record gives a start of Feb 2015, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine